Informations générales (source: ClinicalTrials.gov)
HUSH Restriction in HIV Infected Patients
Observational
ANRS, Emerging Infectious Diseases (Voir sur ClinicalTrials)
octobre 2019
septembre 2023
29 juin 2024
HIV eradication faces a major obstacle that is viral persistence in latent reservoir
cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral
transgene latency and several epigenetic regulators have been involved in this process.
Among them, the "Human Silencing Hub" or HUSH complex, composed of Tasor, MPP8 and
periphilin, has been shown to recruit the H3K9me3 methyltransferase "SET domain
bifurcated 1" (SETDB1) and is therefore responsible for genes' epigenetic repression. Our
recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to
reactivate latent viruses in a latency model. We propose here to study HUSH activity
along pathogenesis.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Necker-Enfants Malades | Claudine DUVIVIER, MD | Contact (sur clinicalTrials) | |||
| IFSI DE L'HÔPITAL BICÊTRE | Antoine CHERET, MD | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôtel-Dieu - 75004 - Paris - France | Jean-Paul VIARD, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria for group 1:
- Symptomatic or asymptomatic acute HIV1 infection
- Age above 15 years old
- No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure)
Inclusion Criteria for group 2:
- Chronic HIV1 infection
- Age above 18 years old
- No ARV treatment since at least 3 month (regardless the reason)
Inclusion Criteria for group 3:
- HIV2 Infection
- Age above 18 years old
- No ARV treatment since at least 3 month (regardless the reason)
Exclusion Criteria for all groups:
- HIV1 and HIV2 co-infection
- Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV,
tuberculosis, HTLV1)
- Life-threatening pathology
- Symptomatic or asymptomatic acute HIV1 infection
- Age above 15 years old
- No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure)
Inclusion Criteria for group 2:
- Chronic HIV1 infection
- Age above 18 years old
- No ARV treatment since at least 3 month (regardless the reason)
Inclusion Criteria for group 3:
- HIV2 Infection
- Age above 18 years old
- No ARV treatment since at least 3 month (regardless the reason)
Exclusion Criteria for all groups:
- HIV1 and HIV2 co-infection
- Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV,
tuberculosis, HTLV1)
- Life-threatening pathology